

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics (P&T) Committee

Thursday, March 18, 2020, 6:00 - 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference

(408) 638-0968

Meeting ID: 950 9421 9058

Passcode: **pharmacy21**

<https://zoom.us/j/95094219058>

AGENDA

- | | | | |
|--|--------------|------|--------|
| 1. Roll Call / Establish Quorum | Dr. Lin | 6:00 | 5 min |
| 2. Public Comment
Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes. | Dr. Lin | 6:05 | 5 min |
| 3. Open Meeting Minutes
Review Santa Clara Family Health Plan (SCFHP) 4Q 2020 P&T Open Session Minutes.
Possible Action: Approve SCFHP P&T Open Session Minutes | Dr. Lin | 6:10 | 2 min |
| 4. Standing Agenda Items | | | |
| a. Chief Medical Officer Health Plan Updates | Dr. Nakahira | 6:12 | 10 min |
| b. Annual P&T Charter Review
Possible Action: Approve P&T Charter | Dr. Huynh | 6:22 | 3 min |
| c. Medi-Cal Rx Update | Dr. Huynh | 6:25 | 5 min |
| d. Grievance & Appeals Report – 4Q 2020 | Ms. Luong | 6:30 | 5 min |
| e. Annual Policy Review | Dr. Huynh | 6:35 | 3 min |
| i. PH.01 Pharmacy and Therapeutics Committee | | | |
| ii. PH.02 Formulary Development and Guideline Management | | | |
| iii. PH.03 Prior Authorization | | | |
| iv. PH.04 Pharmacy Clinical Programs and Quality Monitoring | | | |
| v. PH.05 Continuity of Care for Pharmacy Services | | | |
| vi. PH.06 Pharmacy Communications | | | |
| vii. PH.07 Drug Recalls | | | |
| viii. PH.08 Pain Management Drugs for Terminally Ill | | | |
| ix. PH.09 Medications for Members with Behavioral Health Conditions | | | |
| x. PH.11 340B Program Compliance | | | |
| xi. PH.14 Medications for Cancer Clinical Trial
Possible Action: Approve Pharmacy Policies | Dr. Otomo | 6:38 | 2 min |
| f. Plan/Global Medi-Cal Drug Use Review | Dr. Nguyen | 6:40 | 5 min |
| g. Emergency Supply Report – 1Q 2020 | | | |

Adjourn to Closed Session

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

<p>5. Closed Meeting Minutes Review SCFHP 4Q 2020 P&T Closed Session Minutes. Possible Action: Approve SCFHP P&T Closed Session Minutes</p>	Dr. Lin	6:45	2 min
<p>6. Metrics & Financial Updates</p> <ul style="list-style-type: none"> a. Membership Report b. Pharmacy Dashboard c. Pharmacy Member Portal Stats – 2H 2020 d. Drug Utilization & Spend – 4Q 2020 	Dr. Nakahira	6:47	3 min
	Dr. Otomo	6:50	3 min
	Dr. Huynh	6:53	1 min
	Dr. McCarty	6:54	10 min
<p>7. Discussion and Recommendations for Changes to SCFHP’s Cal MediConnect Formulary & Coverage Determination Criteria</p> <ul style="list-style-type: none"> a. Pharmacy Benefit Manager 4Q 2020 P&T Minutes b. Pharmacy Benefit Manager 1Q 2021 P&T Part D Actions <p>Possible Action: Approve MedImpact Minutes & Actions</p>	Dr. McCarty	7:04	5 min
<p>8. Discussion and Recommendations for Changes to SCFHP’s Medi-Cal Formulary & Prior Authorization Criteria</p> <ul style="list-style-type: none"> a. Old Business/Follow-Up b. Formulary Modifications <p>Possible Action: Approve Formulary Addition and Modification Recommendations</p> <ul style="list-style-type: none"> c. Fee-for-Service Contract Drug List Comparability <p>Possible Action: Approve CDL Comparability Formulary Recommendations</p> <ul style="list-style-type: none"> d. Prior Authorization Criteria <ul style="list-style-type: none"> i. <u>New Criteria</u> 1. Movantik (Naloxegol) ii. <u>Annual Review</u> 1. Letairis (Ambrisentan) 2. Jadenu (Deferasirox) 3. Vumerity (Diroximel fumarate) 4. Gilenya (Fingolimod) 5. General utilization management 6. Copaxone (Glatiramer acetate) 7. Avonex & Rebif (Interferon beta-1a) 8. Savella (Milnacipran) 9. Opioid - Reauthorization 10. Oxycontin (Oxycodone) 11. Evista (Raloxifene) <p>Possible Action: Approve PA Criteria Recommendations</p>	Dr. Otomo	7:09	5 min
		7:14	3 min
	Dr. McCarty	7:17	3 min
	Dr. Nguyen	7:20	5 min
<p>9. New Drugs and Class Review</p> <ul style="list-style-type: none"> a. Nexletol & Nexlizet – Hyperlipidemia b. Aducanumab - Alzheimer’s Disease Review c. COVID-19 Treatments <p>Possible Action: Approve New Drug and Class Recommendations</p> <ul style="list-style-type: none"> d. <u>Informational Only</u> <ul style="list-style-type: none"> i. Ponesimod – Multiple Sclerosis ii. Umbralisib – Lymphoma 	Dr. McCarty	7:25	30 min

- iii. Dasiglucagon – Hypoglycemia
- iv. New & Expanded Indications
- v. New Derivatives, Formulations, & Combinations

Reconvene in Open Session

10. Discussion Items

- a. New and Generic Pipeline

Dr. McCarty 7:55 5 min

11. Adjournment

Next meeting Thursday, June 17, 2021

Dr. Lin 8:00

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com